Chunghwa Chemical Synthesis & Biotech Co Ltd Asset Resilience Ratio
Chunghwa Chemical Synthesis & Biotech Co Ltd asset resilience ratio. Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has an Asset Resilience Ratio of 0.21% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chunghwa Chemical Synthesis & Biotech Co defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chunghwa Chemical Synthesis & Biotech Co Ltd (2009–2023)
Asset resilience ratio of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2009 to 2023. This chart shows how Chunghwa Chemical Synthesis & Biotech Co Ltd's Asset Resilience Ratio has changed over time. Read Chunghwa Chemical Synthesis & Biotech Co debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chunghwa Chemical Synthesis & Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chunghwa Chemical Synthesis & Biotech Co total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$10.70 Million | 0.21% |
| Total Liquid Assets | NT$10.70 Million | 0.21% |
Asset Resilience Insights
- Limited Liquidity: Chunghwa Chemical Synthesis & Biotech Co Ltd maintains only 0.21% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chunghwa Chemical Synthesis & Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chunghwa Chemical Synthesis & Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Chunghwa Chemical Synthesis & Biotech Co Ltd Asset Resilience Ratio by Year (2009–2023)
Chunghwa Chemical Synthesis & Biotech Co Ltd asset resilience ratio by year from 2009 to 2023. The table below shows the annual Asset Resilience Ratio data for Chunghwa Chemical Synthesis & Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.21% | NT$10.70 Million ≈ $337.11K |
NT$5.17 Billion ≈ $162.94 Million |
+0.44pp |
| 2022-12-31 | -0.23% | NT$-10.70 Million ≈ $-337.11K |
NT$4.56 Billion ≈ $143.80 Million |
+0.01pp |
| 2021-12-31 | -0.24% | NT$-10.70 Million ≈ $-337.11K |
NT$4.38 Billion ≈ $138.02 Million |
+0.10pp |
| 2020-12-31 | -0.34% | NT$-10.70 Million ≈ $-337.11K |
NT$3.15 Billion ≈ $99.15 Million |
-0.03pp |
| 2019-12-31 | -0.31% | NT$-10.70 Million ≈ $-337.11K |
NT$3.44 Billion ≈ $108.34 Million |
+0.02pp |
| 2018-12-31 | -0.33% | NT$-10.70 Million ≈ $-337.11K |
NT$3.22 Billion ≈ $101.49 Million |
-0.02pp |
| 2017-12-31 | -0.31% | NT$-10.70 Million ≈ $-337.11K |
NT$3.45 Billion ≈ $108.63 Million |
+0.08pp |
| 2016-12-31 | -0.39% | NT$-10.70 Million ≈ $-337.11K |
NT$2.73 Billion ≈ $85.87 Million |
-0.02pp |
| 2015-12-31 | -0.37% | NT$-10.70 Million ≈ $-337.11K |
NT$2.87 Billion ≈ $90.44 Million |
-0.04pp |
| 2014-12-31 | -0.33% | NT$-10.70 Million ≈ $-337.11K |
NT$3.21 Billion ≈ $101.05 Million |
-1.39pp |
| 2012-12-31 | 1.05% | NT$31.76 Million ≈ $1.00 Million |
NT$3.02 Billion ≈ $95.00 Million |
+1.04pp |
| 2010-12-31 | 0.02% | NT$422.00K ≈ $13.30K |
NT$2.37 Billion ≈ $74.68 Million |
+0.00pp |
| 2009-12-31 | 0.02% | NT$351.00K ≈ $11.06K |
NT$2.31 Billion ≈ $72.85 Million |
-- |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more